NCT03230383 - A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

May 3, 2018

Study Completion Date

May 3, 2018

Conditions

Healthy Subjects

Interventions

DRUG

PF-06865571

Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

DRUG

PF-06865571

Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

DRUG

PF-06865571

Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

DRUG

PF-06865571

Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

DRUG

PF-06865571

Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

DRUG

PF-06865571

Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

DRUG

PF-06865571

Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

DRUG

Placebo

Matching Placebo for PF-06865571 for each cohort.

Trial Locations (2)

06511

Pfizer New Haven Clinical Research Unit, New Haven

B-1070

Pfizer Clinical Research Unit, Brussels